EcoDrugPlus

Fyn Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSSLDG00000013902
Gene Symbol: FYN
4 Cross references
196 Possible Orthologues:

G Protein-Coupled Receptor 119

Ensembl ID : ENSSLDG00000002039
Gene Symbol: GPR119
2 Cross references
174 Possible Orthologues:

G Protein-Coupled Receptor 84

Ensembl ID : ENSSLDG00000000585
Gene Symbol: GPR84
3 Cross references
113 Possible Orthologues:

G1/s-Specific Cyclin-D1-Like

Ensembl ID : ENSSLDG00000009043
Gene Symbol: LOC111670038
4 Cross references
198 Possible Orthologues:

Hck Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSSLDG00000003055
Gene Symbol: HCK
3 Cross references
202 Possible Orthologues:

Il2 Inducible T Cell Kinase

Ensembl ID : ENSSLDG00000002242
Gene Symbol: ITK
3 Cross references
205 Possible Orthologues:

Janus Kinase 1

Ensembl ID : ENSSLDG00000002783
Gene Symbol: JAK1
3 Cross references
212 Possible Orthologues:

Janus Kinase 2

Ensembl ID : ENSSLDG00000009968
Gene Symbol: JAK2
3 Cross references
194 Possible Orthologues:

Kras Proto-Oncogene, Gtpase

Ensembl ID : ENSSLDG00000022168
Gene Symbol: KRAS
3 Cross references
207 Possible Orthologues:

Malt1 Paracaspase

Ensembl ID : ENSSLDG00000003415
Gene Symbol: MALT1
3 Cross references
195 Possible Orthologues:

Map Kinase-Activated Protein Kinase 2-Like

Ensembl ID : ENSSLDG00000006641
Gene Symbol: LOC111667188
3 Cross references
174 Possible Orthologues:

Mapk Activated Protein Kinase 2

Ensembl ID : ENSSLDG00000006571
Gene Symbol: MAPKAPK2
4 Cross references
187 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).